Physician profile
Travis Lloyd
NPI 1255520466
$2,089.30
in general payments reported to CMS, 2019-2025
29 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.08 · 2020: $281 · 2021: $550 · 2022: $410 · 2023: $300 · 2024: $176 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $799 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $798.55 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $421.05 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $185.67 | 2021-2022 | |
| Axsome Therapeutics, INC. | $159.72 | 2023-2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $146.63 | 2020-2021 | |
| Amgen INC. | $132.71 | 2020-2025 | Evenity, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $131.64 | 2020-2021 | |
| Exact Sciences Corporation | $98.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.73 | 2025 | Caplyta |
| Currax Pharmaceuticals LLC | $65.72 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $62.59 | 2022 | |
| Pfizer INC. | $58.50 | 2022-2024 | |
| Lilly USA, LLC | $53.73 | 2022-2025 | Mounjaro, Kisunla |
| Teva Pharmaceuticals USA, INC. | $51.69 | 2021 | |
| Merck Sharp & Dohme LLC | $50.27 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.29 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $39.53 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $39.33 | 2023-2024 | Rexulti, Abilify Maintena |
| Kyowa Kirin, INC. | $30.21 | 2019-2023 | Crysvita |
| Astrazeneca Pharmaceuticals Lp | $28.76 | 2019-2021 | |
| Edwards Lifesciences Corporation | $28.73 | 2025 | Sapien 3 Ultra Resilia |
| Sanofi-Aventis U.S. LLC | $25.61 | 2020-2021 | |
| Eisai INC. | $24.96 | 2022 | |
| Bausch Health US, LLC | $18.87 | 2022 | |
| Optinose US, INC. | $18.87 | 2020 | |
| Seqirus USA INC | $18.22 | 2022 | |
| Allergan, INC. | $18.05 | 2020 | |
| Abbott Laboratories | $17.38 | 2022 | |
| Almatica Pharma LLC | $16.10 | 2024 | Loreev Xr |
| Genentech USA, INC. | $15.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Lloyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.